Legal piperazine-containing party pills – a new trend in substance misuse

References

• Wilkins C, Sweetsur P, Casswell S. Recent population trends in amphetamine use in New Zealand: comparison of findings from national household drug surveying in 1998, 2001 and 2003. N Z Med J 2006; 119: 1–10, Accessed at http://www.nzma.org.nz/journal/119-1244/2285/
   Google Scholar
• Wilkins C, Bhatta K, Pledger M, Casswell S. Ecstasy use in New Zealand: findings from the 1998 and 2001 National Drug Surveys. N Z Med J 2003; 116: 383–393
   PubMedGoogle Scholar
• New Zealand Herald. Restraints on party pills delayed. New Zealand Herald, 2 April 2005. http://www.nzherald.co.nz/search/story.cfm?storyid=4CE0F228-39DE-11DA-8E1B-A5B353C55561 accessed 29 January 2007
   Google Scholar
• TVNZ News. High dosage party pills sold in Christchurch, 25 January 2006. http://tvnz.co.nz/view/page/653425 accessed 19 January 2007
   Google Scholar
• Armstrong S. Legal highs: the new ‘social tonics’?. New Statesman 2007; 135(4815), http://www.newstatesman.com/200610230025 accessed 19 January 2007
   Google Scholar
• Perrott A. High Gear. Canvas April, 2005; 2: 10–12
   Google Scholar
• Wilkins C, Girling M, Sweetsur P, Huckle T, Huakau J. Legal party pill use in New Zealand: prevalence of use, availability, health harms and ‘gateway effects’ of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP). Centre for Social and Health Outcomes Research and Evaluation (SHORE), Massey University, Auckland 2006
   Google Scholar
• Wilkins C, Reilly J, Rose E, Roy D, Pledger M, Lee A. The socio-economic impact of amphetamine type stimulants in New Zealand: final report. Centre for Social and Health Outcomes Research and Evaluation, Massey University, Auckland 2004
   Google Scholar
• Wilkins C, Girling M, Sweetsur P, Butler R. Methamphetamine and other illicit drug trends in New Zealand 2005. Findings from the Methamphetamine Module of the 2005 Illicit Drug Monitoring System (IDMS). SHORE/Whariki. Massey University, Auckland 2005; 9
   Google Scholar
• Wilkins C, Girling M, Sweetsur P, Butler R. Cannabis and other illicit drug trends in New Zealand 2005. Findings from the Cannabis Module of the 2005 Illicit Drug Monitoring System (IDMS). SHORE/Whariki. Massey University, Auckland 2005; 8
   Google Scholar
• Wilkins C, Girling M, Sweetsur P, Butler R. Hallucinogens and other illicit drug trends in New Zealand 2005. Findings from the Hallucinogen Module of the 2005 Illicit Drug Monitoring System (IDMS). SHORE/Whariki. Massey University, Auckland 2005; 8
   Google Scholar
• Bye C, Munro-Faure A D, Peck A W, Young P A. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973; 6: 163–169
   PubMed Web of Science ®Google Scholar
• Malomvolgyi B, Tothfalusi L, Tekes K, Magyar K. Comparison of serotonin agonistic and antagonistic activities of a new antidepressant agent Trelibet (EGYT-475) and its metabolite EGYT-2760 on isolated rat fundus. Acta Physiol Hung. 1991; 78: 201–209
   PubMed Web of Science ®Google Scholar
• Magyar K. Pharmacokinetic aspects of the mode of action of EGYT-475, a new antidepressant agent. Pol J Pharmacol Pharm 1987; 39: 107–112
   PubMedGoogle Scholar
• Fantegrossi W, Winger G, Woolverton W, Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 2005; 772: 161–168
   Google Scholar
• Baumann M, Clark R, Budzynski A, Partilla J, Blough B, Rothman R. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’). Neuropsychopharmacology 2005; 30: 550–560
   PubMed Web of Science ®Google Scholar
• Tekes K, Tothfalusi L, Malomvolgyi B, Herman F, Magyar K. Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm 1987; 39: 203–211
   PubMedGoogle Scholar
• Campbell H, Cline W, Evans M, Lloyd J, Peck A W. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1973; 6: 170–176
   PubMed Web of Science ®Google Scholar
• Shulgin A. Pihkal: a chemical love story. Transform Press, Berkley, CA 1991
   Google Scholar
• Erowid. Benzylpiperazine: Legal Status, 2004. http://www.erowid.org/chemicals/bzp/bzp_law.shtml accessed 29 January 2007
   Google Scholar
• Schoeffter P, Hoyer D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?. Naunyn Schmiedebergs Arch Pharmacol 1989; 339: 675–683
   PubMedGoogle Scholar
• Grotewiel M, Chu H, Sanders-Bush E. m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. J Pharmacol Exp Ther 1994; 27: 1122–1126
   Google Scholar
• Conn P, Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis- linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther 1987; 242: 552–557
   PubMed Web of Science ®Google Scholar
• Schechter M. Use of TFMPP stimulus properties as a model of 5-HT1B receptor activation. Pharmacol Biochem Behav 1988; 31: 53
   PubMedGoogle Scholar
• Herndon J, Pierson M, Glennon R. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl) piperazine. Pharmacol Biochem Behav 1992; 43: 739
   PubMed Web of Science ®Google Scholar
• Staack R, Paul L, Springer D, Kraemer T, Maurer HH. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 2004; 67: 235–244
   PubMed Web of Science ®Google Scholar
• Staack R F, Fritschi G, Maurer H H. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J Chromatog B: Analyt Technol Biomed Life Sci 2002; 773: 35–46
   PubMed Web of Science ®Google Scholar
• Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 2006; 118: 1–10, Accessed at http://www.nzma.org. nz/journal/118-1227/1784/
   Google Scholar
• O'Dell L, Kreifeldt M, George F, Ritz M C. The role of serotonin(2) receptors in mediating cocaine-induced convulsions. Pharmacol Biochem Behav 2000; 65: 677–681
   PubMedGoogle Scholar
• Pasini A, Tortorella A, Gate K. The anticonvulsant action of fluoxetine in substantia nigra is dependent upon endogenous serotonin. Brain Res 1996; 724: 84–88
   PubMed Web of Science ®Google Scholar
• Bhattachary S, Powell J. Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or ‘ecstasy’: evidence for cognitive impairment. Psychol Med 2001; 31: 647–658
   PubMed Web of Science ®Google Scholar
• Barr A, Panenka W, MacEwan G, Thornton A, Lang D, Honer W, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006; 31: 301–313
   PubMed Web of Science ®Google Scholar
• Green R, Mechan A, Elliott J M, O'Shea E, Colado M. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev 2003; 55: 463–508
   PubMed Web of Science ®Google Scholar
• Murray J B. Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol 1998; 132: 227–237
   PubMed Web of Science ®Google Scholar
• Rawson R A, Anglin M D, Ling W. Will the methamphetamine problem go away?. J Addict Dis 2002; 21: 5–19
   PubMed Web of Science ®Google Scholar
• Volkow N D, Chang L, Wang G J, Fowler J S, Franceschi D, Sedler M, et al. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry 2001; 158: 383–389
   PubMed Web of Science ®Google Scholar
• Parrott A. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001; 16: 557–577
   PubMed Web of Science ®Google Scholar
• Austin H, Monasterio E. Acute psychosis following ingestion of ‘Rapture’. Australas Psychiatry 2004; 12: 406–408
   PubMedGoogle Scholar
• Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. NZ Med J 5 May, 2006; 119: 1–3, Accessed at: http://www.nzma.org.nz/journal/119-1233/1959/
   Google Scholar
• Claridge A. Pill casualties down 50%. The Press, Christchurch, 27 September 2006
   Google Scholar
• Nicholson T C. Prevalence of use, epidemiology and toxicity of ‘herbal party pills’ among those presenting to the emergency department. Emerg Med Australas 2006; 18: 180–184
   PubMedGoogle Scholar
• Rajaratnam S MW, Arendt J. Health in a 24-h society. Lancet 2001; 358: 999–1005
   PubMed Web of Science ®Google Scholar
• Williamson A M, Feyer A. Moderate sleep deprivation produces impairments in cognitive and motor performance equivalent to legally prescribed levels of alcohol intoxication. Occup Environ Med 2000; 57: 649–655
   PubMed Web of Science ®Google Scholar
• Curcio G, Ferrara M, De Gennaro L. Sleep loss, learning capacity and academic performance. Sleep Med Rev 2006; 10: 323–337
   PubMed Web of Science ®Google Scholar
• Dahl R E, Lewin D S. Pathways to adolescent health sleep regulation and behavior. J Adolesc Health 2002; 31(6, Suppl. 1)175–184
   PubMedGoogle Scholar
• Candor Trust. Party pills and driving – the wider issues. Scoop Independent News, S I News, 18 January 2007 http://www.scoop.co.nz/stories/PO0701/S00075.htm accessed 29 January 2007
   Google Scholar
• Marshall J. Party pill study aborted over ‘severe adverse events’. New Zealand Herald, 21 January 2007. http://www.nzherald.co.nz/search/story.cfm?storyid=0008CFE2-B3B2-15B2-AEE683027AF10192 accessed 29 January 2007
   Google Scholar
• Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004; 23: 319–344
   PubMed Web of Science ®Google Scholar
• Brookhuis K, Waard D, Samyn N. Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety. Psychopharmacology 2004; 73: 440–445
   Google Scholar
• Parrott A, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 1998; 139: 261–268
   PubMed Web of Science ®Google Scholar
• Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug. Br J Addict 1992; 87: 1161–1172
   PubMedGoogle Scholar
• Curran H V, Travill R A. Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week-end ‘high’ followed by mid-week low. Addiction 1997; 92: 821–831
   PubMed Web of Science ®Google Scholar
• Vincent N, Shoobridge J, Ask A, Allsop S, Ali R. Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug Alcohol Rev 1998; 17: 187–195
   PubMed Web of Science ®Google Scholar
• Vollenweider F, Gamma A, Liechti M, Huber T. Psychological and cardiovascular efffects and short-term sequelae of MDMA (‘ecstasy’) in MDMA-naive health volunteers. Neuropsychopharmacology 1998; 19: 241–251
   PubMed Web of Science ®Google Scholar
• Banwell C, Dance P, Quinn C, Davies R, Hall D. Alcohol, other drug use, and gambling among Australian Capital Territory (ACT) workers in the building and related industries. Drugs: Educ Prevent Pol 2006; 13: 167–178
   Web of Science ®Google Scholar
• South N. Managing work, hedonism and ‘the borderline’ between the legal and illegal markets: two case studies of recreational heavy drug users. Addiction Res Theory 2005; 12: 525–538
   Google Scholar
• Ministry of Health. National Drug Policy: A National Drug Policy for New Zealand 1998 – 2003. Ministry of Health, Wellington 1998
   Google Scholar
• Wilkins C, Reilly J, Casswell S. Cannabis ‘tinny’ houses in New Zealand; implications for the use of cannabis and other drugs in New Zealand. Addiction 2005; 100: 971–980
   PubMed Web of Science ®Google Scholar
• Bedford K, Nolan S, Onrust R, Siegers J. The illicit preparation of morphine and heroin from pharmaceutical products containing codeine: ‘homebake’ laboratories in New Zealand. Forensic Sci Int 1987; 34: 197–204
   PubMedGoogle Scholar
• Social Tonics Association of New Zealand. Code of Practice for the Manufacture, Labelling, Distribution and Marketing of Social Tonics in New Zealand. 2005, http://www.stanz.org.nz/Code%20of%20Practice%20-%20%20Post%20Consultation%20Final%20Draft.pdf accessed 22 January 2007
   Google Scholar
• Expert Advisory Committee on Drugs. The Expert Advisory Committee on Drugs (EACD): advice to the Minister on: benzylpiperazine (BZP):. EACD, Wellington 2004
   Google Scholar
• Expert Advisory Committee on Drugs. Further EACD advice on Benzylpiperazine (BZP) and related substances. Expert Advisory Committee on Drugs, Wellington 2006
   Google Scholar
• Drug Enforcement Administration. Department of Justice. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule. Federal Register 2004; 69: 12794–12797
   PubMedGoogle Scholar
• Baumann M, Clark R, Budzynski A, Partilla J, Blough B, Rothman R. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’). Neuropsychopharmacology 2004; 28: 1–11
   Google Scholar
• McCandless D. Clubbers snap up new legal high. Guardian, Manchester, 13 December 2005. http://www.guardian.co.uk/uk_news/story/0,3604,1665787,00.html accessed 29 January 2007
   Google Scholar
• News Item. ACMD refers benzylpiperazine (BZP) issue to Europe: P.E.P Pills, 2006; http://www.pep-pills.co.uk/news/news-items/acmd-ferers-bzp-issue-to-europe accessed 22 January 2007
   Google Scholar
• Parker H. Normalization as a barometer: recreational drug use and the consumption of leisure by younger Britons. Addiction Res Theory 2005; 13: 205–215
   Web of Science ®Google Scholar
• Falck R S, Carlson R G, Wang J, Siegal H A. Sources of information about MDMA (3,4-methylenedioxymethamphetamine): perceived accuracy, importance, and implications for prevention among young adult users. Drug Alcohol Depend 2004; 74: 45–54
   PubMed Web of Science ®Google Scholar